Additionally, a meta-analysis comprising eight studies and 1051 patients with ovarian cancer demonstrated a positive correlation between CD133 levels and tumour stage (odds ratio (OR) = 0.26, 95% CI 0.12–0.58, p = 0.001, random effect), as well as an association of CD133 overexpression with reduced 2-year overall survival (OR = 1.67, 95% CI 1.06–2.63, p = 0.03, fixed effect), but not with histological type (OR = 1.10, 95% CI 0.82–1.47, p = 0.54, fixed effect) or response to treatment (OR = 0.84, 95% CI 0.61–1.16, p = 0.29, fixed effect) [136]. The gene discussed is PROM1; the disease is ovarian cancer.